Analysts review Keros Therapeutics Inc’s rating


Keros Therapeutics Inc’s recently made public that its Chief Financial Officer Regnante Keith unloaded Company’s shares for reported $1.81 million on Nov 04. In the deal valued at $45.29 per share,40,000 shares were sold. As a result of this transaction, Regnante Keith now holds 0 shares worth roughly $0.0.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Then, Regnante Keith sold 20,000 shares, generating $908,367 in total proceeds. Upon selling the shares at $45.42, the Chief Financial Officer now owns 0 shares.

Before that, Regnante Keith sold 20,000 shares. Keros Therapeutics Inc shares valued at $955,872 were divested by the Chief Financial Officer at a price of $47.79 per share. As a result of the transaction, Regnante Keith now holds 0 shares, worth roughly $0.0.

Wells Fargo initiated its Keros Therapeutics Inc [KROS] rating to an Overweight in a research note published on Tuesday, December 08, 2023; the price target was $60.

Price Performance Review of KROS

On Tuesday, Keros Therapeutics Inc [NASDAQ:KROS] saw its stock fall -2.04% to $56.18. Over the last five days, the stock has gained 7.48%. Keros Therapeutics Inc shares have risen nearly 41.30% since the year began. Nevertheless, the stocks have risen 4.95% over the past one year. While a 52-week high of $59.96 was reached on 01/25/24, a 52-week low of $27.02 was recorded on 01/02/24. SMA at 50 days reached $45.53, while 200 days put it at $39.41. A total of 0.31 million shares were traded, compared to the trading of 0.33 million shares in the previous session.

Levels Of Support And Resistance For KROS Stock

The 24-hour chart illustrates a support level at 54.54, which if violated will result in even more drops to 52.89. On the upside, there is a resistance level at 57.50. A further resistance level may holdings at 58.81. The Relative Strength Index (RSI) on the 14-day chart is 60.75, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.74, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 28.64%. Stochastics %K at 65.81% indicates the stock is a holding.

How much short interest is there in Keros Therapeutics Inc?

A steep rise in short interest was recorded in Keros Therapeutics Inc stocks on Jan 31, 2024, growing by 0.4 million shares to a total of 1.77 million shares. Yahoo Finance data shows the prior-month short interest on Dec 29, 2023 was 1.37 million shares. There was a rise of 22.6%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 7.68% of the overall stock float, the days-to-cover ratio (short ratio) rose to 3.23.

Most Popular